GlassScriptPhysician profile
Bita Motesharrei
NPI 1164496675
$3,879.33
in general payments reported to CMS, 2019-2025
32 companies · $686 in 2025
The $686 reported for 2025 was more than what 87% of Obstetrics providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $188 · 2021: $671 · 2022: $588 · 2023: $829 · 2024: $577 · 2025: $686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,059 · Education: $32.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,059.01 |
| Education | $32.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $594.57 | 2021-2025 | |
| Abbvie INC. | $521.02 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $308.66 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $294.94 | 2023-2025 | Veozah |
| Renovia INC | $242.94 | 2021 | |
| Aspira Women'S Health INC | $184.55 | 2022-2025 | Ova1 |
| Exeltis, USA INC. | $166.70 | 2021-2025 | Slynd |
| Therapeuticsmd, INC. | $148.31 | 2019-2022 | |
| Evofem Biosciences, INC. | $147.27 | 2020-2023 | Phexxi |
| Millicent US INC | $140.28 | 2023-2025 | Femring, Intrarosa, Femlyv |
| Avion Pharmaceuticals | $138.85 | 2019-2022 | |
| Pfizer INC. | $117.20 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $110.86 | 2020-2025 | |
| Myovant Sciences INC. | $109.96 | 2021-2022 | |
| Organon LLC | $97.12 | 2023 | Nexplanon |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $70.06 | 2024-2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $69.70 | 2023-2025 | Accrufer |
| Daiichi Sankyo INC. | $47.63 | 2021-2024 | Injectafer |
| Sage Therapeutics, LLC | $44.97 | 2024-2025 | Zurzuvae |
| Molnlycke Health Care US, LLC | $43.17 | 2024 | Mepilex Border Post-Op Ag |
| Roche Diagnostics Corporation | $38.07 | 2019 | |
| Amag Pharmaceuticals, INC. | $35.78 | 2019 | |
| Becton, Dickinson and Company | $30.61 | 2024 | Bd Max System, Bd Max Instrument |
| Lupin INC. | $28.47 | 2019 | |
| Exact Sciences Corporation | $27.47 | 2025 | The Cologuard Plus Collection Kit |
| Supernus Pharmaceuticals, INC. | $21.53 | 2025 | Qelbree |
| Scynexis, INC. | $17.99 | 2022 | |
| Astellas Pharma Global Development | $17.48 | 2024 | Veozah |
| Coopersurgical, INC. | $17.21 | 2019 | |
| Allergan, INC. | $16.35 | 2019 | |
| Dysis Medical, INC. | $14.93 | 2022 | |
| Hologic Sales and Service, LLC | $14.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bita Motesharrei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.